Piper Sandler Companies (PIPR)
(Delayed Data from NYSE)
$259.90 USD
-8.66 (-3.22%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $260.23 +0.33 (0.13%) 6:40 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
PIPR 259.90 -8.66(-3.22%)
Will PIPR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PIPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PIPR
Moelis (MC) Beats Q2 Earnings and Revenue Estimates
Piper Sandler Companies (PIPR) Surges 4.2%: Is This an Indication of Further Gains?
PIPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Carlyle Group (CG) Eyes Buyout of Baxter's Kidney Care Unit
Robinhood (HOOD) Buys Pluto Capital, Eyes Wealth Business
BlackRock (BLK) to Buy Preqin, Boost Private Markets Abilities
Other News for PIPR
Piper Sandler Companies to Announce Second Quarter 2024 Financial Results and Host a Conference Call on August 2, 2024
Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.
CRWD Stock Alert: Hold Off On CrowdStrike After Disastrous IT Outage
Morgan Stanley: Technically Fair, But Mid-Market Still Better
Piper Sandler: Biotech And ECM Is Back Online